Luciano Jason A, Zuckerbraun Brian S
Department of Surgery, University of Pittsburgh, 200 Lothrop St, Pittsburgh, PA 15213, USA.
Department of Surgery, University of Pittsburgh, 200 Lothrop St, Pittsburgh, PA 15213, USA; Department of Surgery, VA Pittsburgh Healthcare System, University Drive, Pittsburgh, PA 15240, USA.
Surg Clin North Am. 2014 Dec;94(6):1335-49. doi: 10.1016/j.suc.2014.08.006. Epub 2014 Sep 27.
Clostridium difficile is increasing in both incidence and severity. Although metronidazole and vancomycin remain the gold standard for medical management, and surgical colectomy the gold standard for surgical management, new treatment alternatives, including the creation of a diverting loop ileostomy along with colonic lavage and vancomycin enemas, are being investigated that may lead to changes in the current treatment algorithms. The most exciting development in the treatment options for C difficile infection, however, is likely to be novel immunologic agents, which hold the potential to reduce the incidence, mortality, and costs associated with C difficile.
艰难梭菌的发病率和严重程度都在上升。尽管甲硝唑和万古霉素仍是药物治疗的金标准,手术结肠切除术仍是手术治疗的金标准,但包括创建转流性袢状回肠造口术并联合结肠灌洗和万古霉素灌肠在内的新治疗方案正在研究中,这可能会导致当前治疗方案的改变。然而,艰难梭菌感染治疗方案中最令人兴奋的进展可能是新型免疫制剂,其有可能降低与艰难梭菌相关的发病率、死亡率和成本。